Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

Navigating the Financial Aspects of CAR T-Cell Therapy

In science and medicine, information is constantly changing and may become out-of-date as new data emerge. All articles and interviews are informational only, should never be considered medical advice, and should never be acted on without review with your health care team.

Dr. Brian Koffman, chief medical officer of CLL Society, was quoted in the WebMD article, Navigating the Financial Aspects of CAR T-Cell Therapy. CAR-T therapy is an experimental treatment option for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL / SLL) that is only available to patients through clinical trials. While CAR-T therapy is a promising treatment option, it is also associated with considerably high costs. In this WebMD article, Dr. Koffman provides practical advice on how patients can receive assistance paying for this expensive and potentially lifesaving therapy.

Based on the recent positive results from the TRANSCEND CLL 004 Trial of the investigational CAR-T therapy lisocabtagene maraleucel (liso-cel) in CLL, the CLL Society hopes to see FDA approval soon. CLL Society has resources to help you better understand CAR-T therapy and is active in getting these novel therapies approved and made affordable to those who might benefit.